Skip to content
AiONAiON

Gastrointestinal effects (overall)

The set of digestive complaints recorded in REDEFINE-1 with CagriSema: they occurred in 79.6% of participants compared with 39.9% on placebo. Most were mild or moderate and short-lived.

Institutional endorsement by Clínica Evolution

This entry is for information. Your case requires an individual medical assessment.